2,116 followers
@JacobPlieth $AZN AZD7442 mAbs were modeled after nirsevimab which does not contain LALA or other Fc-inactivating mutations. However some publications suggest that YTE mutations themselves lead to loss of effector function: https://t.co/hZr9Sy4jzS